Last updated on January 2020

Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months


Brief description of study

The purpose of this study is to evaluate the efficacy of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in WD patients aged 12 and older.

Clinical Study Identifier: NCT03403205

Find a site near you

Start Over

University of Michigan

Ann Arbor, MI United States
  Connect »

Baylor College of Medicine

Houston, TX United States
  Connect »

Seattle Children's Hospital

Seattle, WA United States
  Connect »

Austin Health

Heidelberg, Australia
  Connect »

Alfred Hospital

Melbourne, Australia
  Connect »

Texas Children's Hospital

Houston, TX United States
  Connect »

Queen Mary Hospital

Hong Kong, Hong Kong
  Connect »

Asan Medical Center

Seoul, Korea, Republic of
  Connect »

Seoul National University

Seoul, Korea, Republic of
  Connect »

Kings College Hospital

Brixton, United Kingdom
  Connect »